| 1 |
34240438 | Fingerprint loss during combination therapy using osimertinib and anlotinib: A case report. | 2022 Feb |
1 |
| 2 |
34391686 | EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. | 2022 Mar |
2 |
| 3 |
34689382 | Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy. | 2022 Jan |
2 |
| 4 |
34881519 | Multicenter real-world data of patients harboring rare mutations other than EGFR or ALK in advanced or metastatic non-small cell lung cancer. | 2022 Feb |
1 |
| 5 |
35046665 | Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study. | 2022 |
2 |
| 6 |
35379563 | An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib. | 2022 Apr 2 |
1 |
| 7 |
35598358 | The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. | 2022 May 19 |
1 |
| 8 |
33199228 | A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). | 2021 Mar |
1 |
| 9 |
33338859 | Evolving multidisciplinary treatment of squamous cell carcinoma of the head and neck in India✰. | 2021 |
1 |
| 10 |
33613698 | A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study). | 2021 |
1 |
| 11 |
33685865 | Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. | 2021 May 15 |
2 |
| 12 |
33745863 | Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA. | 2021 Jul |
1 |
| 13 |
33928022 | First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | 2021 |
2 |
| 14 |
34036692 | Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study. | 2021 Aug |
1 |
| 15 |
34070597 | Polymorphisms in EGFR Gene Predict Clinical Outcome in Unresectable Non-Small Cell Lung Cancer Treated with Radiotherapy and Platinum-Based Chemoradiotherapy. | 2021 May 25 |
2 |
| 16 |
34180588 | Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation. | 2021 Aug |
1 |
| 17 |
34292495 | Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. | 2021 Dec |
1 |
| 18 |
34326746 | Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation. | 2021 May-Aug |
1 |
| 19 |
34389637 | Amivantamab Is Active in Platinum-Resistant EGFR ex20-mutant NSCLC. | 2021 Oct |
1 |
| 20 |
34400966 | Cetuximab-decorated and NIR-activated Nanoparticles Based on Platinum(IV)-prodrug: Preparation, Characterization and In-vitro Anticancer Activity in Epidermoid Carcinoma Cells. | 2021 Winter |
1 |
| 21 |
34589972 | Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. | 2021 Jan |
1 |
| 22 |
34616674 | Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI. | 2021 |
1 |
| 23 |
34818606 | Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. | 2021 Dec |
1 |
| 24 |
34964780 | Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: A meta-analysis. | 2021 Nov 24 |
1 |
| 25 |
31837576 | Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher. | 2020 Feb |
2 |
| 26 |
32088115 | Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation. | 2020 May |
1 |
| 27 |
32336530 | EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. | 2020 Jul |
1 |
| 28 |
32376116 | Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival. | 2020 Sep |
1 |
| 29 |
32569853 | Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis. | 2020 Sep |
1 |
| 30 |
32749686 | Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma. | 2020 Oct 15 |
1 |
| 31 |
32753889 | Sequential Whole Exome Sequencing Reveals Somatic Mutations Associated with Platinum Response in NSCLC. | 2020 |
1 |
| 32 |
32945394 | Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC. | 2020 Oct |
2 |
| 33 |
32957736 | Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. | 2020 Sep 17 |
2 |
| 34 |
33037105 | Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. | 2020 Nov |
1 |
| 35 |
33163410 | Treatment Patterns and Survival Outcomes of Non-Small Cell Lung Cancer Patients Initially Diagnosed With Brain Metastases in Real-World Clinical Practice. | 2020 |
1 |
| 36 |
30478887 | EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer. | 2019 Apr |
2 |
| 37 |
30640563 | Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice. | 2019 Mar |
1 |
| 38 |
30778772 | The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. | 2019 Feb 18 |
1 |
| 39 |
30885350 | Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy. | 2019 Apr |
2 |
| 40 |
31262883 | Broad-spectrum Cross-resistance to Anticancer Drugs Mediated by Epidermal Growth Factor Receptor. | 2019 Jul |
1 |
| 41 |
31292359 | Treatment of Non-small Cell Lung Cancer with EGFR-mutations. | 2019 |
1 |
| 42 |
31315599 | Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation. | 2019 Jul 17 |
1 |
| 43 |
31346466 | A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab. | 2019 |
2 |
| 44 |
31347029 | Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis. | 2019 Oct |
3 |
| 45 |
31597567 | Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy. | 2019 Oct 10 |
1 |
| 46 |
31648503 | [Efficacy of first generation EGFR-TKIs and chemotherapy as first-line therapy in advanced lung adenocarcinoma patients with uncommon EGFR mutations]. | 2019 Oct 23 |
1 |
| 47 |
31676542 | Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance. | 2019 Nov |
1 |
| 48 |
31728434 | Excellent platinum dependent response to chemotherapy after relapse under TKI treatment in NSCLC with sensitizing EGFR mutations and no detectable resistance mutations: three case studies. | 2019 |
1 |
| 49 |
31807168 | Epidermal growth factor receptor mutation subtype has differential effects on adjuvant chemotherapy for resected adenocarcinoma pathological stages II-III. | 2019 Dec |
4 |
| 50 |
29369176 | Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma. | 2018 Jan |
6 |